| Vol. 15.00 – 6 January, 2023 |
| |
|
|
| In three applications of the approach, human CD64t-engineered thyroid epithelial cells, pancreatic beta cells, and CAR T cells withstood clinically relevant levels of graft-directed antibodies and fully evaded antibody-mediated killing. [Nature Biotechnology] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| In Pdcd1fl/flFoxp3eGFP−Cre-ERT2(+/−) mice, in which both PD-1-expressing and PD-1-deficient Treg cells coexisted in the same tissue environment, conditional deletion of PD-1 in Treg cells resulted in impairment of the proliferative and suppressive capacity of tumor infiltrating Treg cells. [Nature Immunology] |
|
|
|
| To investigate the role of sterol regulatory binding protein (SREBP) signaling in modulating immune responses, researchers generated mice with B cell- or CD11c+ antigen-presenting cell-specific deletion of SCAP, an essential regulator of SREBP signaling. [Nature Immunology] |
|
|
|
| Scientists developed an engineered probiotic that noninvasively monitored and recorded inflammatory bowel disease occurrence and progression in real time, and could release treatments via a self-tunable mechanism in response to these biomarkers. [Cell Host & Microbe] |
|
|
|
| The authors demonstrated that targeting human leukocyte antigens and PD-L1 alone did not sufficiently protect stem cell-derived islet cells from xenograft- or allograft-rejection. [Cell Reports Medicine] |
|
|
|
| Talaporfin sodium photodynamic therapy (TS-PDT) induced apoptosis, necrosis, and autophagy-associated cell death were tested in vitro. Tumor growth was inhibited in the TS-PDT and anti-PD-1 antibody combination group, compared with other single treatment or non-treatment groups, in vivo. [Molecular Therapy-Oncolytics] |
|
|
|
| Scientists developed a genetically engineered probiotic delivery system that delivered a peptide to the intestinal tract with high efficacy. They constructed an inducible system in the probiotic Lactobacillus reuteri to secrete the Kv1.3 potassium blocker ShK-235. [Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| The authors demonstrated that CXCL4 binds to glycosaminoglycan sugars on proteoglycans within the endothelial extracellular matrix, resulting in increased adhesion of leukocytes to the vasculature, increased vascular permeability, and non-specific recruitment of a range of leukocytes. [Cell Reports] |
|
|
|
| In a murine TNF–induced sepsis model, TRIF and CD14 deficiency decreased systemic inflammation, reduced organ pathology, and improved survival. [Science Immunology] |
|
|
|
|
| The authors discuss the heterogeneity of interleukin-17-producing CD4+ T cells (TH17), and the role of this heterogeneity in diverse functions of TH17 cells from homeostasis to tissue inflammation. [Nature Immunology] |
|
|
|
|
| BioNTech has signed a memorandum of understanding with the UK government. The aim is to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either through clinical trials or as authorized treatments. [BioNTech] |
|
|
|
| STEMCELL Technologies announced that its President and CEO, Dr. Allen Eaves, has been appointed to the Order of Canada by Her Excellency the Right Honorable Mary Simon, the Governor General of Canada. [STEMCELL Technologies] |
|
|
|
|
| February 19 – 22, 2023 Banff, Alberta, Canada |
|
|
|
|
|
| University of California, San Diego – La Jolla, California, United States |
|
|
|
| STEMCELL Technologies – St. Egreve, France |
|
|
|
| Pfizer – Cambridge, Massachusetts, United States |
|
|
|
| Pfizer – Pearl River, New York, United States |
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, United States |
|
|
|
|